To Abreviate or not to Abreviate [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2010-04-24 10:16 (5896 d 21:14 ago) – Posting: # 5210
Views: 18,545

Dear KR,

sorry if I contributed to the obfuscation of your thread.
I read briefly through the document from the OGD and it does confuse me somewhat.
As far as I can tell, this calls for an assessment of relative potency via a rudimentary dose-response curve and bootstrap. Validating a stats package for the botstrap is one hurdle in itself.

But, actually, in order to assess relative potency I would believe that something more complex than a three-arm study would be needed, so I cannot tell you exactly which groups to have. I cannot tell if the FDA wants to see just the dose-response for Ref and then a single point of Test. If they will accept it, it would to me seem to be three arms and should be easy, but does the Emax model given in the document really allow for that?

Best regards
EM.

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
156 visitors (0 registered, 156 guests [including 20 identified bots]).
Forum time: 07:30 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5